Long-term remote ischemic preconditioning to improve heart blood flow and outcomes after CABG
Official title: Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After Coronary Artery Bypass Grafting
Run by Henan Institute of Cardiovascular Epidemiology · NCT04779008 · Data updated 2026-11-12
This trial tries whether repeated arm‑cuff blood‑flow interruptions (remote ischemic preconditioning) can improve heart blood flow and outcomes for people having CABG.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 210 (estimated) |
| Sponsor | Henan Institute of Cardiovascular Epidemiology Academic / other |
| Locations | 1 site (Zhengzhou, Henan) |
| Status | Recruiting |
| Started | March 10, 2021 |
| Main results expected | December 1, 2025 |
| Study ends | December 1, 2026 |
| Registry record updated | September 18, 2025 |
| Trial ID | NCT04779008 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with three‑vessel coronary artery disease scheduled for elective CABG who can tolerate arm‑cuff ischemia, are not taking glibenclamide or nicorandil, and can provide informed consent.
✕Probably not a fit
Patients who may not receive benefit include those with upper‑limb peripheral vascular disease, recent acute MI with cardiogenic shock, severe organ dysfunction, uncontrolled severe hypertension, pregnancy, inability to tolerate RIPC, or those on interfering medications such as glibenclamide or nicorandil.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
A total of 210 patients with three‑vessel coronary disease scheduled for CABG are randomized 1:1:1 into three groups (70 each): a repeated RIPC group receiving one preoperative RIPC and daily post‑operative RIPC for 1 year, a single RIPC group receiving one preoperative RIPC only, and a control group receiving no RIPC. RIPC is delivered as four cycles of 5 minutes of upper‑arm ischemia by cuff inflation to 200 mmHg alternating with 5 minutes of reperfusion. Myocardial blood flow is quantitatively measured at 7 days and 3 months, blood biomarkers (VEGF, nitric oxide, adenosine, endothelin‑1) are tracked, and MACCE (cardiovascular death, nonfatal MI, unplanned revascularization, stroke) is recorded at 6 and 12 months. The trial is conducted at Fuwai Central China Cardiovascular Hospital (Zhengzhou, Henan) with in‑person cuff treatments and imaging follow‑ups.
Why it matters
Potential benefit: If successful, repeated RIPC could improve myocardial perfusion after CABG and reduce major cardiovascular events such as heart attack, stroke, or repeat revascularization.
How similar studies have gone: Two large randomized trials showed that a single preoperative RIPC reduced perioperative troponin release but did not improve long‑term outcomes, making prolonged daily RIPC a relatively novel and less‑tested approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Three coronary artery lesions, CABG surgery was planned Exclusion Criteria: * The patients could not tolerate ripc; * peripheral vascular disease affecting upper limbs * Acute myocardial infarction complicated with cardiogenic shock，in recent 30 days, * Emergency cases * Severe structural heart disease and severe arrhythmia ； * The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively; * Severe liver, renal and pulmonary disease * Mental disorder can't cooperate; * Inability to give informed consent； * Patients on glibenclamide or nicorandil, as these medications may interfere with RIC * pregnant;
Where it's running
-
Fuwai central China cardiovascular Hospital
Zhengzhou, Henan, China Recruiting
Study contacts
- Principal investigator: Muwei Li, Ph.D — Fuwai central China cardiovascular hospotial
- Study coordinator: Quan Guo, MD
- Email: xinyiguoquan@163.com
- Phone: +8615670510031
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
Predicting how coronary artery disease progresses in adults 45 and younger
This project will try to build prediction models using coronary CT scans and health data from people aged 18–45 to see who is more likely to have plaque get worse over time.
-
Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions
This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.
-
Italian Cardiac Rehabilitation Registry for Coronary Disease and Heart Failure
This registry collects real-world information to see how cardiac rehabilitation programs work for adults recovering from coronary disease or heart failure across Italy.
-
Orbital atherectomy versus standard balloon strategy for calcified coronary bifurcation lesions
This study tests whether using orbital atherectomy before stenting helps adults with moderately or severely calcified coronary bifurcation lesions get better stent results than the standard balloon-first approach.
-
Healthy Nordic diet's effects on heart disease
This study is testing if following a Healthy Nordic diet can help people with coronary heart disease improve their heart health over 18 months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.